Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1

Blood ◽  
2001 ◽  
Vol 97 (12) ◽  
pp. 3721-3726 ◽  
Author(s):  
Ilka Ott ◽  
Martin Andrassy ◽  
Dominik Zieglgänsberger ◽  
Stefanie Geith ◽  
Albert Schömig ◽  
...  

In acute myocardial infarction (AMI), monocyte procoagulant activity is increased and may contribute to the risk for recurrence and other thrombotic events. This study sought to investigate the role tissue factor (TF) and tissue factor pathway inhibitor-1 (TFPI-1) in the regulation of monocyte procoagulant activity in AMI. Serial venous blood samples were obtained from 40 patients with AMI undergoing revascularization by stent placement. Twenty patients with elective stenting for stable angina served as control subjects. TF proteolytic activity was measured with spectrozyme factor Xa (FXa), TF and TFPI-1 surface expression on monocytes by flow cytometry, RNA expression in whole blood by reverse transcription–polymerase chain reaction, and concentrations of plasma prothrombin fragments F1 + 2 by immunoassay. Forty-eight hours after AMI, an increase was found in TF RNA, followed by an increase in TF surface expression by 24% ± 4% and in plasma concentration of F1 + 2 by 103% ± 17% (P < .05). These changes could not be attributed to the intervention because they did not occur in the control group. TFPI-1 RNA and binding to the monocyte surface remained unchanged. FXa generation by monocytes of patients with AMI increased 53.6% ± 9% in the presence of polyclonal antibodies to TFPI-1, indicating that cell-associated TFPI-1 inhibits monocyte TF activity. The increased monocyte procoagulant activity in AMI was caused by an up-regulation of TF that was partially inhibited by surface-bound TFPI-1. Anticoagulant therapy by direct inhibition of TF activity may, thus, be particularly effective in AMI.

2000 ◽  
Vol 75 (2-3) ◽  
pp. 267-274 ◽  
Author(s):  
Nobuyasu Yamamoto ◽  
Hisao Ogawa ◽  
Shuichi Oshima ◽  
Hirofumi Soejima ◽  
Hiromi Fujii ◽  
...  

2001 ◽  
Vol 78 (2) ◽  
pp. 115-119 ◽  
Author(s):  
Vanessa Roldán ◽  
Francisco Marín ◽  
Pascual Fernández ◽  
Juan Luján ◽  
Juan G. Martínez ◽  
...  

Circulation ◽  
2002 ◽  
Vol 105 (3) ◽  
pp. 279-281 ◽  
Author(s):  
Ilka Ott ◽  
Valerie Malcouvier ◽  
Albert Schömig ◽  
Franz-Josef Neumann

Author(s):  
Yuko Kamikura ◽  
Hideo Wada ◽  
Atsushi Yamada ◽  
Minori Shimura ◽  
Katsuyo Hiyoyama ◽  
...  

1998 ◽  
Vol 79 (05) ◽  
pp. 919-923 ◽  
Author(s):  
Eriko Morishita ◽  
Takuma Hashimoto ◽  
Hidesaku Asakura ◽  
Masanori Saito ◽  
Masahide Yamazaki ◽  
...  

SummaryTissue factor pathway inhibitor (TFPI) is present in a free-form and in lipoprotein-associated forms in plasma. In this study, the plasma concentrations of total TFPI (tTFPI) and free-form TFPI (fTFPI) were measured in 25 patients with Graves’ disease and 25 age-matched healthy subjects, and the relationship between thyroid state and plasma TFPI was examined. Plasma concentrations (median) of tTFPI and fTFPI in Graves’ patients who were hyperthyroid were significantly increased compared with Graves’patients who were euthyroid (152 ng/ml versus 124 ng/ml, p <0.01 and 41.3 ng/ml versus 20.2 ng/ml, p <0.0001, respectively), and control subjects (152 ng/ml versus 96 ng/ml, p <0.0001 and 41.3 ng/ml versus 18.7 ng/ml, p <0.0001, respectively). There was no significant difference in plasma fTFPI concentrations between the euthyroid group and the control group. Plasma fTFPI concentrations correlated closely with thyroid hormone (T3) levels in the patients (r = 0.559, p <0.005). Serial measurement of individual patients revealed that plasma concentrations of fTFPI and tTFPI were significantly decreased, reaching normal control values upon attainment of euthyroidism. In conclusion, the close correlation between plasma fTFPI and serum thyroid hormone levels suggests that thyroid hormones might influence the synthesis or metabolism of TFPI on the surface of endothelial cells in patients with Graves’ disease. This is the first report concerning high concentrations of plasma fTFPI in patients with hyperthyroidism.


Sign in / Sign up

Export Citation Format

Share Document